Диссертация (1146667), страница 19
Текст из файла (страница 19)
— 2012. — Vol. 5. —P. 501–512.10366. Fukuda S. Bifidobacteria can protect from enteropathogenic infectionthrough production of acetate / Fukuda S., Toh H., Hase K. [et al.] // Nature . —2011. — Vol. 469. — P. 543–547.67. Furuya-Kanamori L. Asymptomatic Clostridium difficile colonization:epidemiology and clinical implications [Электронный доступ] / Furuya-KanamoriL., Marquess J., Yakob L. [et al.] // BMC Infect Dis. —2015.
— Vol. 15. Режимдоступа https://www.ncbi.nlm.nih.gov/pubmed/68. Gerding D.N. Clostridium difficile binary toxin CDT: Mechanism,epidemiology, and potential clinical importance / Gerding D.N., Johnson S., RupnikM., Aktories K. // Gut Microbes. —2014. — Vol. 5. — P. 15-27.69. Gerding D.N. Administration of spores of nontoxigenic Clostridiumdifficile strain M3 for prevention of recurrent C. difficile infection: a randomizedclinical trial / Gerding D.N., Meyer T. [et al.] // JAMA.
— 2015. — Vol. 313, №17.— P. 1719-1727.70. Ghantoji S.S. Economic healthcare costs of Clostridium difficileinfection: a systematic review/ Ghantoji S.S., Sail K., Lairson D.R. [et al.] // J HospInfect. — 2010. — Vol. 74. —P. 309–318.71. Goldenberg J.Z. Probiotics for the prevention of Clostridium difficileassociated diarrhea in adults and children [Электронный доступ] /Goldenberg J.Z.,Ma S.S.
[et al.] // Cochrane Database Syst Rev. — 2013. — Vol. 5. Режим доступаhttps://www.ncbi.nlm.nih.gov/pubmed/72. Gosalbes M.J. Metatranscriptomic approach to analyze the functionalhuman gut microbiota [Электронный доступ] / Gosalbes M.J., Durbán A. [et al.] //PLoSONE. —2011. — Vol. 6 Режим доступа www.plosone.org73. Gravel D. Health Care–Associated Clostridium difficile Infection inAdults Admitted to Acute Care Hospitals in Canada: A Canadian Nosocomial104Infection Surveillance Program Study / Gravel D., Miller M.
[et al.] // CID. —2009.— Vol. 48. — P. 568-576.74. Guarner Fr., Khan A. G. WGO Global Guideline Probiotics andprebiotics. // World Gastroenterology Organisation. — 2011.75. Harwani D. The Great Plate Count Anomaly and the UnculturableBacteria // International journal of scientific research. — Vol. 2013. — 2, №9. —P.350-351.76. He M., et al. Evolutionary dynamics of Clostridium difficile over shortandlong-time scales.// Proc Natl.
Acad Sci. USA. —2010. —Vol. 107. — P. 7527–7532.77. Hensgens M. P. Clostridium difficile infection in the community: azoonotic disease? / Hensgens M. P. M., Keessen E. C. [et al.] // Clin MicrobiolInfect. — 2012. — Vol. 18. —P. 635–645.78. Høiby N. ESCMID guideline for the diagnosis and treatment of biofilminfections / Høiby N., Bjarnsholt T., Moser C. // Clinical Microbiology andInfection. — 2015. — Vol. 21. — P. 1.79. Hritani A.
Does Gastrointestinal Dysmotility Predispose to Recurrent orSevere Forms of Clostridium difficile Infections? [Электронный доступ ]/ HritaniA., Alkaddour A. [et al.] // Case Reports in Gastrointestinal Medicine. — 2014.Режим доступа https://www.ncbi.nlm.nih.gov/pubmed/80. Janarthanan S. Clostridium difficile-associated diarrhea and proton pumpinhibitor therapy: a meta-analysis/ Janarthanan S., Ditah I. [et al.] // Am JGastroenterol. — 2012. — Vol. 107, №7.
— P. 1001–1010.81. Jeon S.G. Probiotic Bifidobacterium breve induces IL- 10-producing Tr1cells in the colon [Электронный доступ]/ Jeon S.G., Kayama H., Ueda Y. [et al.] //PLoS Pathog. —2012. — Vol. 8. Режим доступа www.plosone.org10582. Jin L. Species diversity and relative abundance of lactic acid bacteria inthe milk of rhesus monkeys (Macaca mulatta) / Jin L., Hinde K., Tao L. // J. MedPrimatol. — 2011. — Vol.
40, №1. — P. 52–58.83. Johansson M. E. The two mucus layers of colon are organized by theMUC2 mucin, whereas the outer layer is a legislator of host-microbial interactions /Johansson M. E., Larsson J. M., Hansson, G. C. // Proc. Natl Acad. Sci. USA. —2011. — Vol.108. — P. 4659–4665.84. Johansson, M. E.
V. et al. Composition and functional role of the mucuslayers in the intestine // Cell. Mol. Life Sci. —2011. — Vol. 68. — P. 3635–3641.85. Kamboj M. Relapse versus reinfection: surveillance of Clostridiumdifficile infection / Kamboj M., Khosa P., Kaltsas A. [et al.] // Clin.
Infect. Dis. —2011. — Vol. 53. —P. 1003–1006.86. Karanika S. Prevalence and Clinical Outcomes of Clostridium difficileInfection in the Intensive Care Unit: A Systematic Review and Meta-Analysis[Электронный доступ] / Karanika S., Paudel S., Zervou F.N. [et al.] // Open ForumInfectDis.—2015.—Vol.3.Режимдоступаhttps://www.ncbi.nlm.nih.gov/pubmed/87. Karczewski J.
Development of a recombinant toxin fragment vaccine forClostridium difficile infection / Karczewski J., Zorman J., Wang S. [et al.] //Vaccine. —2014. — Vol. 32. — P. 2812–2818.88. Kelly C. P. Can we identify patients at high risk of recurrent Clostridiumdifficile infection? // Clin Microbiol Infect. —2012. — Vol. 18, №6. —P. 21-27.89. Khanna S. Community-acquired Clostridium difficile infection: anincreasing public health threat.// Infection and Drug Resistance.
— 2014. — Vol. 7.—P. 63–72.10690. Khanna S. Clostridium difficile infection: management strategies for adifficult disease / Khanna S., Pardi D. S. // Ther Adv Gastroenterol. —2014. — Vol.7, № 2. — P. 72– 86.91. Khanna S. The epidemiology of community-acquired Clostridium difficileinfection: a population-based study / Khanna S., Pardi D.S. [et al.] //Am JGastroenterol. —2012. — Vol. 107, №1. — P. 89–95.92.
Kim S.C. Advanced chronic kidney disease: a strong risk factor forClostridium difficile infection/ Kim S.C., Seo M.Y. [et al.] // Korean J Intern Med.—2016. — Vol. 31, № 1. — P. 125-133.93. King A. M. Emergence of toxin A-negative, toxin B-positive Clostridiumdifficile strains: epidemiological and clinical considerations / King A. M, Mackin K.E. [et al.] // Future Microbiol. —2015. — Vol. 10, № 1.
— P. 1–4.94. Kinnebrew M. A., Lee Y.J., Jenq R. R., et al. Early Clostridium difficileInfection during allogeneic hematopoietic stem cell transplantation [Электронныйдоступ] / Kinnebrew M. A., Lee Y.J., Jenq R. R., et al. // Plos One. —2014. —9.Режим доступа www.plosone.org95. Klaassens E.S. The fecal bifidobacterial transcriptome of adults: amicroarray approach/ Klaassens E.S., Ben-Amor K., Vriesema A., Vaughan E.E., W.de Vos // Gut Microbes. — 2011.
— Vol. 2. —P. 217–226.96. Knecht H. Effects of b-Lactam Antibiotics and Fluoroquinolones onHuman Gut Microbiota in Relation to Clostridium difficile Associated Diarrheatransplantation [Электронный доступ] / Knecht H., Neulinger S. C., Heinsen F. A.// PLOS ONE. — 2014. — Vol. 9. Режим доступа www.plosone.org97. Kociolek L.K. Breakthroughs in the treatment and prevention ofClostridium difficile infection / Kociolek L.K., Gerding D.N.
// Nat RevGastroenterol Hepatol. — 2016. — Vol. 13, № 3. — P. 150-160.10798. Koo H. Rifaximin: a unique gastrointestinal-selective antibiotic for entericdiseases / Koo H., Dupont H. // Curr Opin Gastroenterol. — 2010. — Vol. 26. — P.17–25.99. Kuijper E. еt al. Update of Clostridium difficile infection due to PCRRibotipe 027 in Europe // Eurosurveillance. – 2008.
— Vol.13. — P. 7–9.100. Kwok C.S. Risk of Clostridium difficile infection with acid suppressingdrugs and antibiotics: meta-analysis / Kwok C.S., Arthur A.K. [et al.] // Am JGastroenterol. —2012. — Vol. 107, № 7. — P. 1011–1019.101. Lahti L. Tipping elements in the human intestinal ecosystem[Электронный доступ] / Lahti L., Salojarvi J., Salonen A. [et al.] // NatureCommunications.—2014.—Vol.5.Режимдоступаhttps://www.ncbi.nlm.nih.gov/pubmed/102. Lamont J. Asymptomatic colonization by Clostridium difficile in infants:implications for disease in later life // J Pediatr Gastroenterol Nutr.
— 2010. — Vol.51. — P.2—7.103. Larocque M. A curated C. difficile strain 630 metabolic network:prediction of essential targets and inhibitors / Larocque M., Chénard T.[et al.] //BMC Systems Biology. — 2014. — Vol. 8. —P. 117-122.104. Lebeer S. Antiinflammatory potential of probiotics: lipoteichoic acidmakes a difference / Lebeer S., Claes I., Vanderleyden J. // Trends Microbiol. —2011. — Vol.
20. — P. 5–10.105. Lee J.H. The changes of PCR ribotype and antimicrobial resistance ofClostridium difficile in a tertiary care hospital over 10 years / Lee J.H., Lee Y., LeeK., Riley T.V., Kim H. // J. Med. Microbiol. — 2014. — Vol. 63 , № 6. —P. 819–823.108106. Lee N.S. Opportunities for Improvement in the Care of PatientsHospitalized for Inflammatory Bowel Disease-Related Colitis / Lee N.S., Pola S.,Groessl E.J.
// Dig Dis Sci. — 2016. — Vol. 61, № 4. —P. 1003-1012.107. Leslie J. L. Persistence and Toxin Production by Clostridium difficilewithin Human Intestinal Organoids Result in Disruption of Epithelial ParacellularBarrier Function / Leslie J. L., Huang S. [et al.] // Infection and Immunity. — 2015.— Vol. 83. —P. 138-145.108. Lewis A. L. Host sialoglycans and bacterial sialidases: a mucosalperspective / Lewis A.
L., Lewis, W. G. // Cell. Microbiol. —2012. — Vol. 14. — P.1174–1182.109. Lichtman J. S. Host-microbiota interactions in the pathogenesis ofantibiotic- associated diseases / Lichtman J. S., Ferreyra J. A. [et al.] // Cell Reports.—2016. — Vol. 14, № 5. — P. 1049–1061.110. Ling Z. et al. Pyrosequencing analysis of the human microbiota of healthyChinese undergraduates [Электронный доступ] // BMC Genomics. —2013. —Vo.14. Режим доступа https://www.ncbi.nlm.nih.gov/pubmed/111.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
